NCT04630366View on ClinicalTrials.gov

A Phase 1, First Time in Humans Study of NST-1024

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions
Hypertriglyceridemia
Interventions
DRUG

NST-1024

NST-1024

DRUG

Placebo

Matching placebo to NST-1024

Trial Locations (1)

LS2 9LH

Covance Leeds Clinical Research Unit, Leeds

Sponsors
All Listed Sponsors
lead

NorthSea Therapeutics B.V.

INDUSTRY